查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485064

生物製劑藥物發現市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、方法、製造類型、地區和競爭細分，2019-2029F

Biologics Drug Discovery Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Method, By Manufacture Type, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球生物製劑藥物發現市場估值為82.3 億美元，預計在預測期內將穩定成長，到2029 年複合年成長率為7.89%。標誌著越來越重視開發源自活生物體的生物製劑治療藥物。生物製劑，包括單株抗體、疫苗和基因療法，為各種疾病提供針對性的創新治療方法，推動藥物發現市場的擴張。慢性病盛行率的增加、生物技術的進步以及對分子生物學的深入了解等因素促進了生物製劑研究的激增。對新穎、更有效的治療方法的不懈追求刺激了對創新藥物發現方法的需求。

市場概況
預測期 2025-2029
2023 年市場規模 82.3億美元
2029 年市場規模 128.6億美元
2024-2029 年複合年成長率 7.89%
成長最快的細分市場 重組蛋白
最大的市場 北美洲

與傳統小分子藥物相比，生物製劑具有針對特定分子途徑的能力，具有較高的療效和較低的副作用。這導致研發活動激增，推動了全球市場。基因組學、蛋白質組學和生物資訊學等技術的融合在加速生物藥物發現方面發揮關鍵作用。這些技術能夠全面了解疾病機制、識別潛在藥物標靶以及最佳化候選治療藥物。人工智慧和機器學習的整合透過預測藥物交互作用和最佳化先導化合物進一步提高了藥物發現流程的效率。

製藥公司、生物技術公司和學術機構之間的合作和夥伴關係正在培育生物製劑藥物發現的協作生態系統。這些合作關係利用不同的專業知識、資源和技術來加速突破性生物療法的開發。監管環境正在不斷發展，以適應生物製品的獨特挑戰和特性。嚴格的監管框架確保了這些複雜療法的安全性和有效性，同時為其開發和批准提供了簡化的途徑。隨著全球生物製劑藥物發現市場在創新和協作努力的推動下持續成長，它不僅解決了未滿足的醫療需求，也重塑了藥物開發的模式。向個人化醫療的轉變和對精準治療的持續追求凸顯了生物製劑在徹底改變全球醫療保健和製藥領域的變革潛力。

主要市場促進因素

慢性病盛行率上升

遠距醫療和遠距醫療的採用

資料互通性和電子健康記錄 (EHR)

主要市場挑戰

資料隱私和安全問題

監管障礙

主要市場趨勢

遠距醫療和虛擬護理擴展

細分市場洞察

類型洞察

方法見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球生物製劑藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（單株抗體、重組蛋白、其他）
    • 依方法（目標辨識/驗證、命中生成/驗證、先導化合物辨識、先導化合物最佳化）
    • 依製造類型（內部、外包）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 5 章：亞太地區生物製劑藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依方法
    • 按製造類型
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲生物製劑藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依方法
    • 按製造類型
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美生物製劑藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依方法
    • 按製造類型
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲生物製劑藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依方法
    • 按製造類型
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲生物製品藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依方法
    • 按製造類型
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 埃及

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球生物製劑藥物發現市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • AbbVie, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca, Plc
  • Bayer AG
  • Bicon Ltd.
  • Boehringer Ingelheim International GmbH.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Catalent, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23850

Global Biologics Drug Discovery Market was valued at USD 8.23 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.89% through 2029. The Global Biologics Drug Discovery Market is witnessing a paradigm shift in the pharmaceutical industry, marked by a growing emphasis on the development of biologics-therapeutic drugs derived from living organisms. Biologics, including monoclonal antibodies, vaccines, and gene therapies, offer targeted and innovative treatment approaches for various diseases, driving the expansion of the drug discovery market. Factors such as the increasing prevalence of chronic diseases, advancements in biotechnology, and a deeper understanding of molecular biology contribute to the surge in biologics research. The relentless pursuit of novel and more effective treatments fuels the demand for innovative drug discovery methods.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 8.23 Billion
Market Size 2029USD 12.86 Billion
CAGR 2024-20297.89%
Fastest Growing SegmentRecombinant Proteins
Largest MarketNorth America

Biologics, with their ability to target specific molecular pathways, exhibit high efficacy and reduced side effects compared to traditional small-molecule drugs. This has led to a surge in research and development activities, propelling the global market. The convergence of technologies such as genomics, proteomics, and bioinformatics plays a pivotal role in accelerating biologics drug discovery. These technologies enable a comprehensive understanding of disease mechanisms, identification of potential drug targets, and optimization of therapeutic candidates. The integration of artificial intelligence and machine learning further enhances the efficiency of drug discovery pipelines by predicting drug interactions and optimizing lead compounds.

Collaborations and partnerships between pharmaceutical companies, biotechnology firms, and academic institutions are fostering a collaborative ecosystem in biologics drug discovery. These partnerships leverage diverse expertise, resources, and technologies to expedite the development of breakthrough biologic therapies. The regulatory landscape is evolving to accommodate the unique challenges and characteristics of biologics. Stringent regulatory frameworks ensure the safety and efficacy of these complex therapies while providing a streamlined pathway for their development and approval. As the Global Biologics Drug Discovery Market continues to grow, fueled by innovation and collaborative efforts, it not only addresses unmet medical needs but also reshapes the landscape of drug development. The shift towards personalized medicine and the ongoing pursuit of precision therapies underscore the transformative potential of biologics in revolutionizing healthcare and pharmaceutical landscapes worldwide.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The Global Biologics Drug Discovery Market is significantly influenced by the rising prevalence of chronic diseases, which has become a global health challenge. Chronic conditions, including diabetes, cardiovascular diseases, respiratory disorders, and obesity, are on the rise, contributing to a growing burden on healthcare systems. Digital health technologies play a pivotal role in addressing the complexities associated with chronic diseases. These technologies offer innovative solutions for continuous monitoring, management, and personalized care delivery. The prevalence of chronic diseases is escalating due to factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population.

Digital health interventions, such as mobile health apps, wearable devices, and remote patient monitoring systems, provide valuable tools for patients and healthcare providers to manage and mitigate the impact of chronic conditions. These technologies enable real-time tracking of vital signs, medication adherence, and lifestyle factors, empowering individuals to actively participate in their health management. Telehealth and virtual care platforms have emerged as crucial components of the response to the rising prevalence of chronic diseases. They facilitate remote consultations, enabling patients to connect with healthcare professionals without the need for in-person visits. This is particularly beneficial for individuals with chronic conditions who require ongoing monitoring and timely interventions.

The integration of digital health solutions into chronic disease management enhances healthcare outcomes by promoting early detection, preventive care, and personalized treatment plans. Machine learning algorithms and data analytics further contribute to the identification of patterns and trends in health data, aiding in predictive interventions and personalized care strategies. Governments, healthcare providers, and industry stakeholders are recognizing the urgency of addressing the rising prevalence of chronic diseases and are increasingly investing in digital health initiatives. The Global Biologics Drug Discovery Market is positioned to play a pivotal role in reshaping healthcare delivery models to effectively meet the challenges posed by the growing burden of chronic conditions, offering scalable and patient-centric solutions that improve overall health outcomes.

Telehealth and Telemedicine Adoption

The Global Biologics Drug Discovery Market is experiencing a transformative wave propelled by the widespread adoption of telehealth and telemedicine. These technologies, collectively known as telehealth, represent a paradigm shift in healthcare delivery, leveraging digital communication tools to connect patients with healthcare providers remotely. The adoption of telehealth has gained significant momentum, driven by factors such as technological advancements, the need for improved accessibility, and the global response to the COVID-19 pandemic. Telehealth encompasses a range of services, including virtual consultations, remote monitoring, and digital communication for healthcare purposes. The convenience and accessibility offered by telehealth have become particularly evident during the pandemic, as individuals seek alternative ways to access healthcare without the need for physical visits to healthcare facilities.

Virtual consultations enable patients to connect with healthcare professionals from the comfort of their homes, improving access to medical advice and reducing the burden on traditional healthcare infrastructures. Remote patient monitoring is another critical aspect of telehealth adoption. Wearable devices and connected health technologies allow for the continuous monitoring of vital signs, chronic conditions, and other health metrics. This real-time data transmission enables healthcare providers to track patients' health status, intervene promptly when needed, and tailor treatment plans based on individualized health insights. The accelerated adoption of telehealth is not only a response to the immediate challenges presented by the pandemic but also indicative of a broader shift in healthcare delivery models. Telehealth offers solutions to geographical barriers, enabling individuals in remote or underserved areas to access healthcare services.

It enhances the overall efficiency of healthcare delivery by reducing wait times, minimizing the need for physical infrastructure, and optimizing healthcare resources. Governments, healthcare organizations, and technology companies are actively investing in the expansion and enhancement of telehealth services. Regulatory frameworks are evolving to support and accommodate the integration of telehealth into mainstream healthcare practices. As telehealth continues to evolve, it is poised to play a central role in the Global Biologics Drug Discovery Market, driving improved patient outcomes, enhancing accessibility, and redefining the dynamics of healthcare delivery on a global scale.

Data Interoperability and Electronic Health Records (EHRs)

Data interoperability and the widespread adoption of Electronic Health Records (EHRs) are pivotal elements reshaping the landscape of the Global Biologics Drug Discovery Market. EHRs serve as comprehensive digital repositories that store patients' health information, medical history, treatment plans, and diagnostic records in electronic formats. The integration of EHRs fosters data interoperability, allowing seamless exchange and accessibility of health information across different healthcare systems and settings. Interoperability enhances care coordination by providing a unified and standardized platform for healthcare professionals to access and share patient data. This connectivity ensures continuity of care, reducing duplication of tests and minimizing medical errors. In emergency situations or when patients seek healthcare services across different providers, interoperable EHRs enable timely access to critical health information, facilitating informed decision-making. The adoption of interoperable EHRs is crucial for achieving a holistic view of a patient's health history. It allows healthcare providers to make well-informed decisions, considering the entirety of a patient's medical background. This comprehensive understanding contributes to more personalized and effective treatment strategies, ultimately improving healthcare outcomes. Interoperable EHRs play a vital role in population health management and public health initiatives.

Aggregated and anonymized data from diverse sources facilitate epidemiological studies, trend analysis, and the identification of health disparities. This data-driven approach enables proactive interventions and targeted public health campaigns. Governments and healthcare regulatory bodies globally are recognizing the importance of data interoperability and EHR adoption. Initiatives and policies are being implemented to encourage standardization and compatibility among different EHR systems. The push for interoperability aligns with the broader goals of improving healthcare quality, reducing healthcare costs, and enhancing the overall efficiency of healthcare delivery. As the Global Biologics Drug Discovery Market evolves, the seamless exchange of health information through interoperable EHRs continues to be a driving force. The integration of these digital records not only streamlines healthcare processes but also sets the foundation for advanced analytics, artificial intelligence applications, and further innovations that contribute to the ongoing transformation of the healthcare ecosystem.

Key Market Challenges

Data Privacy and Security Concerns

Data privacy and security concerns stand out as critical challenges in the evolution of the Global Biologics Drug Discovery Market. As the industry increasingly relies on digital technologies to manage and exchange sensitive health information, safeguarding patient data becomes a paramount priority. The sheer volume and nature of health data make it an attractive target for cyber threats, including hacking, data breaches, and ransomware attacks. One of the primary concerns is ensuring the confidentiality and integrity of patient information. Digital health solutions, such as electronic health records (EHRs), telehealth platforms, and mobile health apps, store a wealth of personal and health-related data. Unauthorized access to this information could lead to privacy violations, identity theft, or misuse of sensitive medical records. Maintaining stringent security measures, including robust encryption protocols and access controls, is crucial to safeguarding the privacy of individuals. The interoperability of digital health systems introduces complexities in managing data across various platforms. The lack of standardized data formats and secure data exchange protocols can create vulnerabilities in the transmission of health information.

Cybersecurity threats, evolving attack vectors, and the need for constant updates to address emerging risks pose ongoing challenges in maintaining a resilient defense against potential breaches. Compliance with data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union, adds another layer of complexity. Adhering to these regulations requires digital health providers to implement robust privacy policies, conduct regular risk assessments, and ensure that patients have control over their data. As the Global Biologics Drug Discovery Market continues to advance, industry stakeholders must prioritize the development and implementation of robust cybersecurity measures. Collaborative efforts between technology developers, healthcare organizations, and regulatory bodies are essential to establishing a secure digital health ecosystem that instills confidence in patients, healthcare providers, and all participants in the digital health landscape. Addressing data privacy and security concerns is not only a regulatory necessity but also fundamental to building trust and fostering the widespread adoption of digital health solutions.

Regulatory Hurdles

Navigating regulatory hurdles poses a significant challenge to the Global Biologics Drug Discovery Market. The rapid evolution of digital health technologies often outpaces the development of clear regulatory frameworks, creating a dynamic landscape where innovations must align with existing standards and compliance requirements. Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are continually adapting their guidelines to accommodate the diverse and rapidly expanding array of digital health solutions. One key regulatory challenge is defining the classification and oversight of digital health technologies. Determining which products fall under the regulatory purview, whether they are medical devices, wellness tools, or software applications, requires precision. The classification often influences the level of scrutiny, testing, and approval processes that digital health products must undergo before entering the market. Ensuring data privacy and security compliance further complicates regulatory considerations.

Striking a balance between fostering innovation and safeguarding patient information becomes intricate, especially when navigating through varying global data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe. The global nature of the Biologics Drug Discovery Market adds an extra layer of complexity as companies seek to comply with different regulatory requirements across regions. Harmonizing regulations internationally is a considerable challenge, given the diversity in healthcare systems, cultural norms, and legal frameworks. The fast-paced nature of digital health innovation introduces the need for agile regulatory processes. Traditional regulatory pathways designed for pharmaceuticals or medical devices may not be adaptable to the rapid iterations and updates common in digital health applications. Striking a balance between ensuring the safety and efficacy of these technologies and allowing for timely market access requires a nuanced approach from regulatory bodies. To address these regulatory challenges, collaboration between industry stakeholders, regulatory agencies, and policymakers is essential. Proactive engagement and ongoing dialogue can help create regulatory frameworks that foster innovation while maintaining high standards of safety, efficacy, and data protection in the Global Biologics Drug Discovery Market.

Key Market Trends

Telehealth and Virtual Care Expansion

Telehealth and virtual care expansion stand as transformative trends in the Global Biologics Drug Discovery Market, reshaping the landscape of healthcare delivery. The widespread adoption of telehealth services and virtual care platforms represents a fundamental shift in how healthcare is accessed and provided. Telehealth, encompassing virtual consultations, remote monitoring, and digital communication for healthcare purposes, has become a cornerstone of modern healthcare systems. One of the key drivers of this expansion is the growing demand for accessible and convenient healthcare services. Telehealth eliminates geographical barriers, allowing patients to connect with healthcare providers from the comfort of their homes. This accessibility is particularly crucial for individuals in remote or underserved areas, enabling them to receive timely medical advice, consultations, and follow-up care. The COVID-19 pandemic has accelerated the adoption of telehealth on a global scale, emphasizing its role in ensuring healthcare continuity during times of crisis. Virtual consultations have become a safer alternative to in-person visits, reducing the risk of exposure to infectious diseases and minimizing the burden on traditional healthcare facilities.

Remote monitoring is another facet of telehealth expansion, empowering patients and healthcare providers with real-time health data. Wearable devices and connected health technologies enable continuous tracking of vital signs, chronic conditions, and other health metrics. This data-driven approach facilitates proactive interventions, personalized treatment plans, and a more comprehensive understanding of patients' health status. The growth of telehealth and virtual care is not only driven by technological advancements but also by evolving patient expectations. Individuals seek healthcare solutions that offer flexibility, convenience, and personalized experiences. Telehealth services fulfill these expectations, providing a convenient avenue for healthcare consultations, reducing travel time, and enhancing overall patient satisfaction. As telehealth continues to expand, it contributes to the ongoing transformation of healthcare delivery models. The integration of virtual care platforms into the broader digital health ecosystem fosters a more patient-centric approach, emphasizing accessibility, efficiency, and improved health outcomes on a global scale.

Segmental Insights

Type Insights

Based on Type, recombinant proteins emerged as the fastest growing segment in the Global Biologics Drug Discovery Market in 2023. This is ascribed due to tits critical role in developing therapeutic biologics. Recombinant proteins, produced through genetic engineering, serve as essential building blocks for biopharmaceuticals. They enable the creation of monoclonal antibodies, cytokines, and other complex proteins crucial for targeted therapies. The segment's dominance is further propelled by advancements in protein engineering technologies, allowing for the design and optimization of recombinant proteins with enhanced efficacy. As the demand for biologics rises in various therapeutic areas, the Recombinant Proteins segment stands out as a key driver, shaping the landscape of biologics drug discovery globally.

Method Insights

Based on method, target identification/validation segment dominated the Global Biologics Drug Discovery Market in 2023. This is because it plays a foundational role in identifying disease-associated targets for therapeutic intervention. Comprehensive understanding of specific targets allows for the development of biologics that precisely target disease pathways. Advances in genomics, proteomics, and bioinformatics bolster target identification capabilities, enhancing accuracy. As the initial step in drug discovery, efficient target identification sets the stage for successful biologics development. The segment's prominence is amplified by the continuous pursuit of novel and validated targets, making Target Identification a critical driver in shaping the global landscape of Biologics Drug Discovery.

Regional Insights

Based on region, North America dominated the global market of biologics drug discovery market in the forecast period. The region benefits from a well-established and sophisticated healthcare infrastructure, fostering advanced research and development capabilities. Major pharmaceutical and biotechnology companies headquartered in North America play a pivotal role, contributing to the innovation and commercialization of biologics. The region hosts numerous leading research institutions and academic centers dedicated to drug discovery. Robust funding mechanisms, a highly skilled workforce, and favorable regulatory frameworks further bolster North America's position. The continuous collaboration between academia and industry, coupled with significant investments in biotechnology, collectively propel the region to the forefront, solidifying its dominance in the global Biologics Drug Discovery market.

Key Market Players

AbbVie, Inc.

Astellas Pharma, Inc.

AstraZeneca PLC

Bayer AG

Bicon Ltd.

Boehringer Ingelheim International GmbH

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Catalent, Inc.

Report Scope:

In this report, the Global Biologics Drug Discovery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biologics Drug Discovery Market, By Type:

    Monoclonal Antibodies Recombinant Proteins Others

Biologics Drug Discovery Market, By Method:

    Target Identification/validation Hit Generation/Validation Lead Identification Lead Optimization

Biologics Drug Discovery Market, By Manufacture Type:

    In-House Outsourced

Biologics Drug Discovery Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biologics Drug Discovery Market.

Available Customizations:

Global Biologics Drug Discovery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Biologics Drug Discovery Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Monoclonal Antibodies, Recombinant Proteins, Others)
    • 4.2.2. By Method (Target Identification/ validation, Hit Generation/ Validation, Lead Identification, Lead Optimization)
    • 4.2.3. By Manufacture Type (In-House, Outsourced)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map

5. Asia Pacific Biologics Drug Discovery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Method
    • 5.2.3. By Manufacture Type
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Biologics Drug Discovery Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Method
        • 5.3.1.2.3. By Manufacture Type
    • 5.3.2. India Biologics Drug Discovery Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Method
        • 5.3.2.2.3. By Manufacture Type
    • 5.3.3. Australia Biologics Drug Discovery Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Method
        • 5.3.3.2.3. By Manufacture Type
    • 5.3.4. Japan Biologics Drug Discovery Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Method
        • 5.3.4.2.3. By Manufacture Type
    • 5.3.5. South Korea Biologics Drug Discovery Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Method
        • 5.3.5.2.3. By Manufacture Type

6. Europe Biologics Drug Discovery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Method
    • 6.2.3. By Manufacture Type
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Biologics Drug Discovery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Manufacture Type
    • 6.3.2. Germany Biologics Drug Discovery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Manufacture Type
    • 6.3.3. Spain Biologics Drug Discovery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Manufacture Type
    • 6.3.4. Italy Biologics Drug Discovery Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Method
        • 6.3.4.2.3. By Manufacture Type
    • 6.3.5. United Kingdom Biologics Drug Discovery Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Method
        • 6.3.5.2.3. By Manufacture Type

7. North America Biologics Drug Discovery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Method
    • 7.2.3. By Manufacture Type
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Biologics Drug Discovery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Manufacture Type
    • 7.3.2. Mexico Biologics Drug Discovery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Manufacture Type
    • 7.3.3. Canada Biologics Drug Discovery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Manufacture Type

8. South America Biologics Drug Discovery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Method
    • 8.2.3. By Manufacture Type
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Biologics Drug Discovery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Manufacture Type
    • 8.3.2. Argentina Biologics Drug Discovery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Manufacture Type
    • 8.3.3. Colombia Biologics Drug Discovery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Manufacture Type

9. Middle East and Africa Biologics Drug Discovery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Method
    • 9.2.3. By Manufacture Type
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Biologics Drug Discovery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Manufacture Type
    • 9.3.2. Saudi Arabia Biologics Drug Discovery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Manufacture Type
    • 9.3.3. UAE Biologics Drug Discovery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Manufacture Type
    • 9.3.4. Egypt Biologics Drug Discovery Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Method
        • 9.3.4.2.3. By Manufacture Type

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Biologics Drug Discovery Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. AbbVie, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Astellas Pharma, Inc.
  • 14.3. AstraZeneca, Plc
  • 14.4. Bayer AG
  • 14.5. Bicon Ltd.
  • 14.6. Boehringer Ingelheim International GmbH.
  • 14.7. Eli Lilly and Company
  • 14.8. F. Hoffmann-La Roche AG
  • 14.9. Gilead Sciences, Inc.
  • 14.10. Catalent, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer